Chimerix to Present at the 36th Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 03, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to provide solutions to the growing population of immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the 36^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 5:00 p.m. PT (8:00 p.m. ET) at the Westin Saint Francis Hotel in San Francisco, CA.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients.  Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new candidate, CMX521, the first direct-acting antiviral in the clinic for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.

CONTACT:
Investor Relations:

[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200

Media:

Marissa Mullane-Hanify
W2O Group
[email protected]
617-337-4159